Antibacterial Agents TRIZ Cases

See how optimized 3'-UTR sequences with stem-loop structures and poly(A) tails extend RNA half-

See how crosslinked cold-water fish gelatin nonwoven fabric resolves poor adhesiveness in wet s

See how topical ammonia oxidizing bacteria reduce pathogenic bacteria, inflammation, and sebum

See how specific 3'-UTR sequences from FCGRT, LSP1, and other genes improve RNA vaccine stabili

See how modified 3′-UTR sequences and optimized poly(A) structures overcome RNA instability and

See how UV photolysis of NO precursors in a closed shower system enables controlled nitrogen mo

See how oleanolic acid acetate from adzuki bean blocks NF-κB and STAT3 signaling to treat infla

See how alternative 3'-UTR sequences from FCGRT, LSP1, and other genes replace duplicated beta-

See how topical ammonia oxidizing bacteria suppress pathogenic bacteria and reduce acne lesions

See how a polymer coating with zwitterion and cationic groups removes leukocytes and platelets

See how multi-stage photolytic NO production with UV-controlled kinetics and circulation-based

See how a polymer coating with zwitterionic and basic nitrogen groups removes leukocytes while

Topical ammonia-oxidizing bacteria reduce P. acnes, inflammation, and sebum while avoiding antibiotic resistance and retinoid risks.

High-pressure hot-water Coptidis extract replaces harsh additives in wet tissues while improving antibacterial cleaning and skin comfort.

Ammonia-oxidizing bacteria convert skin ammonia to nitrite, reducing acne lesions, inflammation, sebum, and resistance risk.

Nanoparticle oxide compositions with boronic ligands and metal ions boost topical antimicrobial action, shortening treatment time while staying skin-tolerant.

Titanium dioxide and quaternary ammonium compounds speed acne treatment by suppressing microbes while reducing skin irritation and scarring.

Moisture-wicking socks release encapsulated antifungal agents during wear, improving treatment compliance and reducing fungal relapse.

Graduated compression, silver nanoparticle yarns, and wool or alpaca fibers help suppress MMP-9, disrupt biofilms, and wick exudate.

Selective EDG-1 modulating compounds improve treatment of lymphocyte-mediated disorders while reducing off-target immunosuppressive side effects.

Guide RNA directs Cas9 to specific DNA sites, enabling precise editing and transcription modulation without redesigning nucleases for each target.

A programmable guide RNA steers reusable Cas9 to chosen DNA sites, avoiding new nuclease design for each target and reducing off-target effects.

Programmable DNA-targeting RNA with inactive Cas9 enables site-specific gene modulation while reducing redesign time and off-target effects.

Adaptive time-constant and gain control lets a power converter identify inductor DCR and maintain stable feedback despite temperature drift.

Lytic enzymes target bacterial surface moieties to kill specific pathogens with high efficacy while reducing resistance linked to broad-spectrum antibiotics.

An RNA guide paired with inactive Cas9 enables site-specific DNA modification and transcription control with fewer redesign steps and off-target effects.

A transport-linked prodrug crosses pulmonary barriers faster, improves local drug concentration, and reduces systemic adverse effects.

Stored power-noise patterns let a DLL pre-adjust clock delay, cutting jitter and phase errors from feedback latency.

Novel indolo-naphthyridine compounds target tumor proliferation and multidrug-resistant bacteria while aiming to reduce chemotherapy limits and side effects.

A shellac-metal liquid dressing forms a self-supporting hydrophobic barrier that stays on animal wounds without bandaging or runoff.

N-aryl mercaptopropionamides block metallo-beta-lactamases, protect imipenem from hydrolysis, and restore activity against resistant Gram-negative bacteria.

Small-molecule dibenzoazepine ligands target the CR3 I-domain to block pathogen binding and entry, reducing Neisseria and retrovirus infection.

Small ferroportin-blocking compounds prevent iron absorption before overload builds, offering longer-lasting treatment with fewer toxic effects.

Binding the PD-L1 C domain at Y134, K162, and N183 blocks PD-1 interaction, boosts T cell response, and inhibits tumor growth.

An insoluble plant polysaccharide fraction adsorbs C. difficile toxins A and B to reduce intestinal damage and help prevent relapse.

Organic solvent extraction and chromatography of Justicia secunda produce antibacterial powders active against MRSA, VRE, and DRSP.

Branched aliphatic amino acids in solid daptomycin cut reconstitution time while maintaining stability and reducing pH dependency.

A fused lysin and human defensin protein targets C. difficile to cut bacterial load and toxin production without relying on antibiotics.

Targeted AAV capsid substitutions help rAAV vectors evade neutralizing antibodies and improve gene delivery in non-immune privileged tissues.

12-epi pleuromutilin derivatives such as BC 9842 gain broad antiviral activity against enveloped RNA viruses while maintaining low cytotoxicity.

By secreting PCV2 ORF2 into culture supernatant, this case shows a faster, higher-yield route to multivalent swine vaccines.

A lyophilized vaginal Lactobacillus powder with trehalose and xylitol improves viability, adherence, and stability for treating abnormal microbiota.

Using pure cannabinoid isolates, polysorbate 80, and sonication, this case achieves a stable injectable pico-emulsion with higher bioavailability.

Combining antibiotics with an NSAID or STAT1 inhibitor helps treat hvKp while suppressing cytokine storm and lowering mortality.

Removing lipid moieties from Mycoplasma vaccine material avoids IL-17A-driven VED while preserving protective immunity and lowering lung lesions.

Bone-targeted bisphosphonate-quinolone conjugates improve osteomyelitis treatment by releasing antibiotic at bone sites while reducing systemic toxicity.

Targeted phages carrying at least 300 sonosensitisers enable selective sonodynamic therapy at low ultrasound intensity with much higher killing efficiency.

Modified chitosan derivatives improve solubility and biocompatibility while boosting antibiotic synergy against resistant bacteria.

Biodegradable micromolded or 3D-printed vaccine formulations enable timed antigen pulses from one injection while improving stability without cold-chain storage.

A killed Lawsonia carbohydrate vaccine enables systemic dosing while preserving protective immunity and avoiding live oral vaccine limits.

Pyrazole amide compounds improve potent, selective inhibition of IRAK family kinases to support treatment of inflammatory and autoimmune conditions.

Nebulized liposomal aminoglycoside targets pulmonary NTM infection to improve lung drug uptake while reducing tolerance limits of conventional therapy.

Targeted IgH locus insertion enables engineered B cells to retain antigen-induced activation, affinity maturation, and antibody secretion.

Ginger-derived exosome-like nanoparticles selectively target P. gingivalis to curb virulence, attachment, and bone loss with low toxicity.

N-aryl mercaptopropionamides bind MBL zinc sites to restore imipenem activity and cut MICs in resistant Gram-negative bacteria.

Defined HSYA, paeoniflorin, and albiflorin compositions simplify Xuebijing actives while retaining sepsis efficacy and safety.

Novel imidazopyrazine derivatives use tuned substitutions and Suzuki coupling to target drug-resistant A. baumannii and P. aeruginosa.

Cultured lung spheroids enable expandable, marker-screened cells that better mimic lung tissue and support fibrosis-reducing therapy.

A six-compound phytochemical blend treats mastitis while avoiding antibiotic residues and resistance, with broader antimicrobial activity.

A dual-binding antibody links CD40-positive APCs with CD137-positive T cells to boost signaling, CD8+ proliferation, and anti-tumor immunity.

Octanoic acid precipitation with vibrating agitation, mild acid treatment, and UVC improves IgM virus safety, yield, and liquid stability.

A hygroscopic nitrite gel generates nitric oxide in situ to avoid toxic NO2 formation while enabling localized, sustained release for wounds and biofilms.

Controlled polysaccharide conjugation and O-acetylation improve meningococcal vaccine immune response across age groups while supporting long-term storage.

A tetrazine-reactive biomaterial depot enables delayed, site-selective drug release with better solubility and fewer systemic side effects.

Modified bovine G-CSF polypeptides use non-natural amino acids to boost neutrophil function and reduce mastitis and respiratory disease in cattle.

New oxathiazinane compounds improve anticancer and antimicrobial activity while reducing toxicity, resistance, and dosing burden through longer half-life.

A multi-strain organic acid-producing microbial consortium suppresses gut pathogens in birds while improving barrier integrity, growth, and mortality.

Thiol-reactive ADC linkers enable site-specific drug attachment, higher payload, and lower off-target toxicity with more consistent conjugate ratios.

Pn3Pase enzymatically strips the serotype 3 pneumococcal capsule, restoring complement deposition and phagocytic killing against resistant strains.

An RNA vaccine primes antigen-specific immunity while PD-1 blockade lifts suppression, improving tumor rejection with lower autoimmune risk.

Targeted polymyxin substitutions lower cytotoxicity and kidney exposure while preserving antibacterial activity against pathogenic strains.

Engineered Lactobacillus continuously secretes anti-infective biomolecules in the digestive tract to extend protection and reduce pathogen colonization.

Synergistic three-drug antibiotic combinations improve killing of resistant bacteria at lower doses, reducing toxicity and development time.

Vaccine-mobilized plasma cell libraries enable recombinant polyclonal proteins with consistent high antibody titers for infection prevention and treatment.

Dual-target antibodies bind PcrV and Psl to block virulence and disrupt biofilms in antibiotic-resistant Pseudomonas infections.

Formulation and peptide parameter changes improve local antimicrobial retention and tissue coverage while lowering toxicity and systemic absorption.

Heating and isolating soluble protein fractions improves prion-like polypeptide detection for diagnosis, disease monitoring, and treatment assessment.

Engineered 3F6 antibodies target staphylococcal antigens to bypass antibiotic resistance and boost opsonophagocytic killing.

When standard antifungals fail against Prototheca strains, ravuconazole and fosravuconazole offer effective treatment for animal infections.

RNA-targeting antibacterial phages use CRISPR-Cas13a to kill drug-resistant bacteria, including plasmid-borne resistance, while sparing normal flora.

Targeting bacterial nucleotidyltransferase enzymes offers a new antibiotic route to treat resistant gram-positive and gram-negative infections.

PTD-MYC fusion proteins or treated immune cells reduce exhausted T cells and strengthen immune response against chronic infection and cancer.

A heat-stable HTRA protease degrades C. difficile toxins without disrupting gut flora, offering an alternative to antibiotics and fecal transplants.

Focusing the S. aureus vaccine on the IsdB NEAT2 subdomain avoids non-protective antibody interference and improves protective immunity.

Medium chain fatty acid salts in a hydrophobic oral polypeptide composition open GI tight junctions to improve absorption and bioavailability.

A vaborbactam-meropenem combination blocks KPC-mediated resistance to improve treatment of UTI and acute pyelonephritis.

Large phospholipid-coated lipid globules help infant formula better mimic human milk, reducing opportunistic pathogens and supporting beneficial bacteria.

Systematic quinolone substituent changes target drug-resistant bacteria while the compound also shows anticancer activity and minimal liver and kidney impact.